Martin Mohren

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Hematological Malignancy, Lymphoid Neoplasia, Elderly Patients +7

Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults—A monocentric German study

Kathleen Jentsch‐Ullrich, Michael Koenigsmann, Martin Mohren et al. · Clinical Immunology · 2005 · 186 citations

Lymphocyte Development, Clinical Population, Immunodeficiencies +9

Thromboembolic complications after splenectomy for hematologic diseases

Martin Mohren, Ilka Markmann, Ulrike Dworschak et al. · American Journal of Hematology · 2004 · 113 citations · Full text

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

Dieter Hoelzer, Andreas Huettmann, Felix Kaul et al. · Blood · 2010 · 83 citations

Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission

Nadežda Basara, Antina Schulze, Ulrich Wedding et al. · Leukemia · 2009 · 79 citations

Hematological Malignancy, Radiation Oncology, Conventional Chemotherapy +15